Treatment regimens for newly diagnosed Ph-positive ALL
| Treatment regimens . | n . | Overall CMR rate, % . | Allogeneic SCT rate, % . | RFS rate, % . | OS rate, % . |
|---|---|---|---|---|---|
| Imatinib | |||||
| High-intensity regimens | |||||
| Lee et al,15 2005 | 20 | 45 | 85 | — | 33 (5-yr) |
| Daver et al,1 2015 | 54 | 45 | 30 | 43 (5-yr) | 43 (5-yr) |
| Yanada et al,16 2006 | 80 | 38 | 61 | 60 (1-yr) | 76 (1-yr) |
| Bassan et al,17 2010 | 59 | — | 72 | 39 (5-yr) | 38 (5-yr) |
| Fielding et al,2 2014 | 175 | — | 71 | 50 (4-yr) | 38 (4-yr) |
| de Labarthe et al,18 2006 | 45 | 29 | 49 | 51 (1.5-yr) | 65 (1.5-yr) |
| Tanguy-Schmidt et al,19 2013 | 45 | 61 | 76 | 44 (4-yr) | 52 (4-yr) |
| Lim et al,20 2015 | 87 | 89 | 64 | 39 (5-yr) | 33 (5-yr) |
| Chalandon et al,21 2015 | 133 | 23 | 65 | 32 (5-yr) | 43 (5-yr) |
| Low-intensity regimens | |||||
| Vignetti et al,22 2007 | 29 | 4 | — | 48 (1-yr) | 74 (1-yr) |
| Chalandon et al,21 2015 | 135 | 28 | 62 | 37 (5-yr) | 46 (5-yr) |
| Dasatinib | |||||
| High-intensity regimens | |||||
| Ravandi et al,3 2015 | 72 | 60 | 17 | 44 (5-yr) | 46 (5-yr) |
| Ravandi et al,4 2016 | 97 | — | 42 | 62 (3-yr) | 69 (3-yr) |
| Low-intensity regimens | |||||
| Foà et al,23 2011 | 53 | 23 | 34 | 51 (1.7-yr) | 69 (1.7-yr) |
| Rousselot et al,24 2016 | 71 | 24 | 10 | 28 (5-yr) | 36 (5-yr) |
| Chiaretti et al,25 2015 | 60 | 19 | 42 | 49 (2.5-yr) | 58 (3-yr) |
| Nilotinib | |||||
| High-intensity regimens | |||||
| Kim et al,26 2015 | 90 | 86 | 70 | 72 (2-yr) | 72 (2-yr) |
| Liu et al,27 2019 | 30 | 83 | 53 | 45 (4-yr) | 45 (4-yr) |
| Low-intensity regimens | |||||
| Ottmann et al,28 2018 | 79 | 58 | 33 | 42 (4-yr) | 47 (4-yr) |
| Chalandon et al,29 2018 | 60 | — | 52 | 85 (1-yr) | 96 (1-yr) |
| Rousselot et al,30 2021 | 156 | — | 58 | 57 (3-yr) | 74 (3-yr) |
| Ponatinib | |||||
| High-intensity regimens | |||||
| Jabbour et al,31 2019 | 86 | 84 | 21 | 68 (5-yr) | 73 (5-yr) |
| Ribera et al,32 2021 | 30 | 47 | 87 | 72 (3-yr) | 97 (3-yr) |
| Low-intensity regimens | |||||
| Martinelli et al,33 2022 | 44 | 41 | 14 | 32 (2-yr) | 66 (2-yr) |
| Blinatumomab-based regimens | |||||
| In combination with dasatinib | |||||
| Foà et al,8 2020 | 63 | 60 | 50 | 71 (3-yr) | 80 (3-yr) |
| In combination with ponatinib | |||||
| Short et al,34 2022 | 35 | 85 | 3 | 93 (2-yr) | 93 (2-yr) |
| Treatment regimens . | n . | Overall CMR rate, % . | Allogeneic SCT rate, % . | RFS rate, % . | OS rate, % . |
|---|---|---|---|---|---|
| Imatinib | |||||
| High-intensity regimens | |||||
| Lee et al,15 2005 | 20 | 45 | 85 | — | 33 (5-yr) |
| Daver et al,1 2015 | 54 | 45 | 30 | 43 (5-yr) | 43 (5-yr) |
| Yanada et al,16 2006 | 80 | 38 | 61 | 60 (1-yr) | 76 (1-yr) |
| Bassan et al,17 2010 | 59 | — | 72 | 39 (5-yr) | 38 (5-yr) |
| Fielding et al,2 2014 | 175 | — | 71 | 50 (4-yr) | 38 (4-yr) |
| de Labarthe et al,18 2006 | 45 | 29 | 49 | 51 (1.5-yr) | 65 (1.5-yr) |
| Tanguy-Schmidt et al,19 2013 | 45 | 61 | 76 | 44 (4-yr) | 52 (4-yr) |
| Lim et al,20 2015 | 87 | 89 | 64 | 39 (5-yr) | 33 (5-yr) |
| Chalandon et al,21 2015 | 133 | 23 | 65 | 32 (5-yr) | 43 (5-yr) |
| Low-intensity regimens | |||||
| Vignetti et al,22 2007 | 29 | 4 | — | 48 (1-yr) | 74 (1-yr) |
| Chalandon et al,21 2015 | 135 | 28 | 62 | 37 (5-yr) | 46 (5-yr) |
| Dasatinib | |||||
| High-intensity regimens | |||||
| Ravandi et al,3 2015 | 72 | 60 | 17 | 44 (5-yr) | 46 (5-yr) |
| Ravandi et al,4 2016 | 97 | — | 42 | 62 (3-yr) | 69 (3-yr) |
| Low-intensity regimens | |||||
| Foà et al,23 2011 | 53 | 23 | 34 | 51 (1.7-yr) | 69 (1.7-yr) |
| Rousselot et al,24 2016 | 71 | 24 | 10 | 28 (5-yr) | 36 (5-yr) |
| Chiaretti et al,25 2015 | 60 | 19 | 42 | 49 (2.5-yr) | 58 (3-yr) |
| Nilotinib | |||||
| High-intensity regimens | |||||
| Kim et al,26 2015 | 90 | 86 | 70 | 72 (2-yr) | 72 (2-yr) |
| Liu et al,27 2019 | 30 | 83 | 53 | 45 (4-yr) | 45 (4-yr) |
| Low-intensity regimens | |||||
| Ottmann et al,28 2018 | 79 | 58 | 33 | 42 (4-yr) | 47 (4-yr) |
| Chalandon et al,29 2018 | 60 | — | 52 | 85 (1-yr) | 96 (1-yr) |
| Rousselot et al,30 2021 | 156 | — | 58 | 57 (3-yr) | 74 (3-yr) |
| Ponatinib | |||||
| High-intensity regimens | |||||
| Jabbour et al,31 2019 | 86 | 84 | 21 | 68 (5-yr) | 73 (5-yr) |
| Ribera et al,32 2021 | 30 | 47 | 87 | 72 (3-yr) | 97 (3-yr) |
| Low-intensity regimens | |||||
| Martinelli et al,33 2022 | 44 | 41 | 14 | 32 (2-yr) | 66 (2-yr) |
| Blinatumomab-based regimens | |||||
| In combination with dasatinib | |||||
| Foà et al,8 2020 | 63 | 60 | 50 | 71 (3-yr) | 80 (3-yr) |
| In combination with ponatinib | |||||
| Short et al,34 2022 | 35 | 85 | 3 | 93 (2-yr) | 93 (2-yr) |
RFS, relapse-free survival.